Christophe Arbet-Engels

CIK: 0001802615

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (14.3%)

Position reduction

Option Exercises (M)1 (14.3%)

Derivative conversions

Awards (A)4 (57.1%)

Compensation grants

Other (G, F, J, C, D, …)1 (14.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

ALT

Altimmune, Inc.

Officer

XFOR

X4 Pharmaceuticals, Inc

Officer

Discretionary Trading P&L

Holdings

Transaction History (7 total)

ALT
Altimmune, Inc.
Oct 1, 2026
Tax Payment(F)
Direct
12.7K shares at avg. $2.76$35K
ALT
Altimmune, Inc.
Oct 1, 2026
Exercise(M)
Direct
37.5K shares-
ALT
Altimmune, Inc.
Oct 1, 2025
Award(A)
Restricted Stock Units
Direct
150K shares-
ALT
Altimmune, Inc.
Oct 1, 2025
Award(A)
Stock Options (option to buy)
Direct
450K shares-
XFOR
X4 Pharmaceuticals, Inc
Feb 12, 2025
Award(A)
Direct
850K shares-
XFOR
X4 Pharmaceuticals, Inc
Jan 24, 2025
Sale(S)
Direct
11.6K shares at avg. $0.45$5K
XFOR
X4 Pharmaceuticals, Inc
Jan 23, 2025
Award(A)
Direct
25.8K shares-

		Type	Shares	Price		Ownership
Oct 1, 2026	ALT Altimmune, Inc.	Tax Payment(F)	12,679	$2.76	$34,994	Direct
Oct 1, 2026	ALT Altimmune, Inc.	Exercise(M)	37,500	-	$0	Direct
Oct 1, 2025	ALT Altimmune, Inc.	Award(A) Restricted Stock Units	150,000	-	-	Direct
Oct 1, 2025	ALT Altimmune, Inc.	Award(A) Stock Options (option to buy)	450,000	-	-	Direct
Feb 12, 2025	XFOR X4 Pharmaceuticals, Inc	Award(A)	850,000	-	-	Direct
Jan 24, 2025	XFOR X4 Pharmaceuticals, Inc	Sale(S)	11,624	$0.45	$5,284	Direct
Jan 23, 2025	XFOR X4 Pharmaceuticals, Inc	Award(A)	25,831	-	$0	Direct

1-7 of 7 transactions

About Arbet-Engels Christophe

Arbet-Engels Christophe (SEC CIK 0001802615) files insider reports with the SEC as Chief Medical Officer of Altimmune, Inc. (ALT) and Chief Medical Officer of X4 Pharmaceuticals, Inc (XFOR).

Signal8 holds 5 ownership filings by Arbet-Engels Christophe (1 Form 3, 4 Form 4), filed between Jan 27, 2025 and Oct 5, 2026. Those filings report 7 transactions, from Jan 23, 2025 to Oct 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Arbet-Engels Christophe's filings is in GAITHERSBURG, MD.

Recent filings by Arbet-Engels Christophe

Oct 1, 2026: Tax withholding of ALT shares (Form 4, code F).
Oct 1, 2026: Option exercise of ALT shares (Form 4, code M).
Oct 1, 2025: Grants or awards of ALT derivative securities (2 lines, Form 4, code A).
Feb 12, 2025: Grant or award of XFOR shares (Form 4, code A).
Jan 24, 2025: Open-market sale of XFOR shares (Form 4, code S).

Other insiders filing for Altimmune, Inc. (ALT)

WEAVER GREGORY L, Chief Financial Officer
MENZIUSO RICHARD THOMAS, Principal Accounting Officer
Richardson Linda M, Chief Commercial Officer
Durso Jerome Benedict, President and CEO
Roberts M Scot, Chief Scientific Officer
Lawver Teri L, Director

How to read Form 4 transaction codes